77 related articles for article (PubMed ID: 18160013)
1. Immunogenicity in macaques of the clinical product for a clade B DNA/MVA HIV vaccine: elicitation of IFN-gamma, IL-2, and TNF-alpha coproducing CD4 and CD8 T cells.
Robinson HL; Sharma S; Zhao J; Kannanganat S; Lai L; Chennareddi L; Yu T; Montefiori DC; Amara RR; Wyatt LS; Moss B
AIDS Res Hum Retroviruses; 2007 Dec; 23(12):1555-62. PubMed ID: 18160013
[TBL] [Abstract][Full Text] [Related]
2. Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques.
Smith JM; Amara RR; McClure HM; Patel M; Sharma S; Yi H; Chennareddi L; Herndon JG; Butera ST; Heneine W; Ellenberger DL; Parekh B; Earl PL; Wyatt LS; Moss B; Robinson HL
AIDS Res Hum Retroviruses; 2004 Jun; 20(6):654-65. PubMed ID: 15242543
[TBL] [Abstract][Full Text] [Related]
3. A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice.
Shephard E; Burgers WA; Van Harmelen JH; Monroe JE; Greenhalgh T; Williamson C; Williamson AL
AIDS Res Hum Retroviruses; 2008 Feb; 24(2):207-17. PubMed ID: 18240963
[TBL] [Abstract][Full Text] [Related]
4. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
5. Studies in macaques on cross-clade T cell responses elicited by a DNA/MVA AIDS vaccine, better conservation of CD8 than CD4 T cell responses.
Smith JM; Amara RR; Wyatt LS; Ellenberger DL; Li B; Herndon JG; Patel M; Sharma S; Chennareddi L; Butera S; McNicholl J; McClure HM; Moss B; Robinson HL
AIDS Res Hum Retroviruses; 2005 Feb; 21(2):140-4. PubMed ID: 15725752
[TBL] [Abstract][Full Text] [Related]
6. DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime.
Smith JM; Amara RR; Campbell D; Xu Y; Patel M; Sharma S; Butera ST; Ellenberger DL; Yi H; Chennareddi L; Herndon JG; Wyatt LS; Montefiori D; Moss B; McClure HM; Robinson HL
AIDS Res Hum Retroviruses; 2004 Dec; 20(12):1335-47. PubMed ID: 15650426
[TBL] [Abstract][Full Text] [Related]
7. Studies on the cross-clade and cross-species conservation of HIV-1 Gag-specific CD8 and CD4 T cell responses elicited by a clade B DNA/MVA vaccine in macaques.
Amara RR; Sharma S; Patel M; Smith JM; Chennareddi L; Herndon JG; Robinson HL
Virology; 2005 Mar; 334(1):124-33. PubMed ID: 15749128
[TBL] [Abstract][Full Text] [Related]
8. Studies on in vitro expression and in vivo immunogenicity of a recombinant MVA HIV vaccine.
Liu J; Wyatt LS; Amara RR; Moss B; Robinson HL
Vaccine; 2006 Apr; 24(16):3332-9. PubMed ID: 16472543
[TBL] [Abstract][Full Text] [Related]
9. Novel HIV IL-4R antagonist vaccine strategy can induce both high avidity CD8 T and B cell immunity with greater protective efficacy.
Jackson RJ; Worley M; Trivedi S; Ranasinghe C
Vaccine; 2014 Sep; 32(43):5703-14. PubMed ID: 25151041
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.
Stebbings R; Février M; Li B; Lorin C; Koutsoukos M; Mee E; Rose N; Hall J; Page M; Almond N; Voss G; Tangy F
PLoS One; 2012; 7(11):e50397. PubMed ID: 23226275
[TBL] [Abstract][Full Text] [Related]
11. Production of intracellular IL-2, TNF-alpha, and IFN-gamma by T cells in B-CLL.
Gallego A; Vargas JA; Castejón R; Citores MJ; Romero Y; Millán I; Durántez A
Cytometry B Clin Cytom; 2003 Nov; 56(1):23-9. PubMed ID: 14582134
[TBL] [Abstract][Full Text] [Related]
12. Studies using a viral challenge and CD8 T cell depletions on the roles of cellular and humoral immunity in the control of an SHIV-89.6P challenge in DNA/MVA-vaccinated macaques.
Amara RR; Ibegbu C; Villinger F; Montefiori DC; Sharma S; Nigam P; Xu Y; McClure HM; Robinson HL
Virology; 2005 Dec; 343(2):246-55. PubMed ID: 16185742
[TBL] [Abstract][Full Text] [Related]
13. Multiprotein HIV type 1 clade B DNA and MVA vaccines: construction, expression, and immunogenicity in rodents of the MVA component.
Wyatt LS; Earl PL; Liu JY; Smith JM; Montefiori DC; Robinson HL; Moss B
AIDS Res Hum Retroviruses; 2004 Jun; 20(6):645-53. PubMed ID: 15242542
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals.
Climent N; Guerra S; García F; Rovira C; Miralles L; Gómez CE; Piqué N; Gil C; Gatell JM; Esteban M; Gallart T
PLoS One; 2011; 6(5):e19644. PubMed ID: 21625608
[TBL] [Abstract][Full Text] [Related]
15. Subtype AE HIV-1 DNA and recombinant Fowlpoxvirus vaccines encoding five shared HIV-1 genes: safety and T cell immunogenicity in macaques.
De Rose R; Chea S; Dale CJ; Reece J; Fernandez CS; Wilson KM; Thomson S; Ramshaw IA; Coupar BE; Boyle DB; Sullivan MT; Kent SJ
Vaccine; 2005 Mar; 23(16):1949-56. PubMed ID: 15734067
[TBL] [Abstract][Full Text] [Related]
16. Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype C.
Burgers WA; Shephard E; Monroe JE; Greenhalgh T; Binder A; Hurter E; Van Harmelen JH; Williamson C; Williamson AL
AIDS Res Hum Retroviruses; 2008 Feb; 24(2):195-206. PubMed ID: 18240957
[TBL] [Abstract][Full Text] [Related]
17. The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection.
Jacobson JM; Zheng L; Wilson CC; Tebas P; Matining RM; Egan MA; Eldridge J; Landay AL; Clifford DB; Luetkemeyer AF; Tiu J; Martinez AL; Janik J; Spitz TA; Hural J; McElrath J; Frahm N;
J Acquir Immune Defic Syndr; 2016 Feb; 71(2):163-71. PubMed ID: 26761518
[TBL] [Abstract][Full Text] [Related]
18. Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation.
Otten GR; Schaefer M; Doe B; Liu H; Megede JZ; Donnelly J; Rabussay D; Barnett S; Ulmer JB
Vaccine; 2006 May; 24(21):4503-9. PubMed ID: 16181711
[TBL] [Abstract][Full Text] [Related]
19. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
Gómez CE; Abaitua F; Rodríguez D; Esteban M
Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
[TBL] [Abstract][Full Text] [Related]
20. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
